Review
Immunology
Rocio Gallego-Duran, Rocio Montero-Vallejo, Douglas Maya-Miles, Ana Lucena, Franz Martin, Javier Ampuero, Manuel Romero-Gomez
Summary: MAFLD is the most prevalent form of liver disease globally, with immune responses playing a key role in its development, leading to various injuries and loss of function in the liver due to metabolic and immune changes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
James B. Maurice, Robert Goldin, Andrew Hall, Jennifer C. Price, Giada Sebastiani, Caryn G. Morse, Laura Iogna Prat, Hugo Perazzo, Lucy Garvey, Patrick Ingiliz, Giovanni Guaraldi, Emmanouil Tsochatzis, Maud Lemoine
Summary: Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease in people living with human immunodeficiency virus (PLWH). This study found a strong association between body mass index and NAFLD, as well as between type 2 diabetes and advanced fibrosis in PLWH. Additionally, further optimization of serological markers for fibrosis is needed.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Guido A. Baselli, Oveis Jamialahmadi, Serena Pelusi, Ester Ciociola, Francesco Malvestiti, Marco Saracino, Luigi Santoro, Alessandro Cherubini, Paola Dongiovanni, Marco Maggioni, Cristiana Bianco, Federica Tavaglione, Annalisa Cespiati, Rosellina M. Mancina, Roberta D'Ambrosio, Valentina Vaira, Salvatore Petta, Luca Miele, Umberto Vespasiani-Gentilucci, Alessandro Federico, Jussi Pihlajamaki, Elisabetta Bugianesi, Anna L. Fracanzani, Helen L. Reeves, Giorgio Soardo, Daniele Prati, Stefano Romeo, Luca VC. Valenti
Summary: This study investigated the impact of rare variants on severe non-alcoholic fatty liver disease, and found that loss-of-function variants in the ATG7 gene promote the progression of NAFLD.
JOURNAL OF HEPATOLOGY
(2022)
Article
Pharmacology & Pharmacy
C. Busca, P. Arias, M. Sanchez-Conde, M. Rico, R. Montejano, L. Martin-Carbonero, E. Valencia, V Moreno, J. Bernardino, A. Olveira, M. Abadia, J. Gonzalez-Garcia, M. L. Montes
Summary: This study aimed to analyze the relationship between PNPLA3, TM6SF2, and MBOAT7-TMC4 and steatosis, steatohepatitis, and liver fibrosis in people living with HIV (PLWHIV) with nonalcoholic fatty liver disease (NAFLD). The results showed that the PNPLA3 G allele variant and MBOAT7-TMC4 A allele variant were associated with steatohepatitis and liver fibrosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Lindsay T. Fourman, Takara L. Stanley, Isabel Zheng, Chelsea S. Pan, Meghan N. Feldpausch, Julia Purdy, Julia Aepfelbacher, Colleen Buckless, Andrew Tsao, Kathleen E. Corey, Raymond T. Chung, Martin Torriani, David E. Kleiner, Colleen M. Hadigan, Steven K. Grinspoon
Summary: This study observed high rates of hepatic fibrosis and progression in patients with HIV-associated NAFLD. Visceral adiposity was identified as a novel predictor of worsening fibrosis. Baseline histologic characteristics did not relate to fibrosis progression.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Gastroenterology & Hepatology
Leke Wiering, Pallavi Subramanian, Linda Hammerich
Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease with a wide range of severity, from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH). NASH can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma, making hepatic fibrosis an important predictor of outcomes. Recent advancements in understanding the activation and inactivation of hepatic stellate cells, which drive fibrosis development, have shed light on the disease progression in NAFLD/NASH.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Winston Dunn, Laurent Castera, Rohit Loomba
Summary: Radiological testing is commonly used for clinical trial prescreening, diagnosis, and treatment, as well as for determining referrals to hepatology specialists. The CAP is effective in detecting fatty liver for NAFLD diagnosis but is unable to differentiate between different grades and track longitudinal changes. MRI-PDFF is a better technique for evaluating longitudinal changes and is used as a primary endpoint in trials for antisteatotic properties of therapeutic agents. The probability of detecting liver fibrosis using radiological testing is high in referral centers for clinical trial prescreening, with reasonable imaging strategies including FIB-4 and VCTE combination, FAST Score, MAST, and MEFIB. However, the probability of detecting liver fibrosis using radiological testing is low when assessing the need for referral to hepatology specialists from primary care. The recommended strategy is the sequential application of FIB-4 and VCTE based on resource availability and local imaging capabilities.
CLINICS IN LIVER DISEASE
(2023)
Article
Pediatrics
Antonella Mosca, Luca Della Volpe, Anna Alisi, Silvio Veraldi, Paola Francalanci, Giuseppe Maggiore
Summary: The study showed that Hepamet and APRI perform better than NFS and FIB-4 in identifying fibrosis in NAFLD patients. However, their positive predictive values are not high enough to be considered diagnostic, indicating the need for further research on new markers for fibrosis.
FRONTIERS IN PEDIATRICS
(2022)
Article
Endocrinology & Metabolism
Nisreen Nimer, Ibrahim Choucair, Zeneng Wang, Ina Nemet, Lin Li, Janet Gukasyan, Taylor L. Weeks, Naim Alkhouri, Nizar Zein, W. H. Wilson Tang, Michael A. Fischbach, J. Mark Brown, Hooman Allayee, Srinivasan Dasarathy, Valentin Gogonea, Stanley L. Hazen
Summary: Metabolomic studies have shown that plasma levels of bile acids are elevated in subjects with NAFLD compared to healthy controls. Specific bile acids are associated with the transition from simple hepatic steatosis to NASH, as well as genetic determinants. This suggests a potential role for bile acid metabolism in the development and progression of NASH.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Letter
Gastroenterology & Hepatology
Amandeep Singh, Rajat Garg, Rocio Lopez, Naim Alkhouri
Summary: This study aims to develop a simple noninvasive fibrosis score to detect advanced fibrosis in patients with diabetes and compare its performance with other fibrosis scores.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Rafael Paternostro, Katharina Staufer, Stefan Traussnigg, Albert-Friedrich Stattermayer, Emina Halilbasic, Omar Keritam, Elias L. Meyer, Judith Stift, Fritz Wrba, Bence Sipos, Ali Canbay, Martin Schlattjan, Elmar Aigner, Christian Datz, Felix Stickel, Clemens Schafmayer, Jochen Hampe, Stephan Buch, Gerhard Prager, Petra Munda, Mattias Mandorfer, Peter Ferenci, Michael Trauner
Summary: Several genetic polymorphisms, including PNPLA3, TM6SF2, and HSD17B13, have been associated with severity of NAFLD. Incorporating these genetic risk factors into risk stratification models may improve predictive accuracy for severity of NAFLD and/or advanced fibrosis on liver biopsy.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Grazia Pennisi, Marco Enea, Alessandra Pandolfo, Ciro Celsa, Michela Antonucci, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Stefanie Parisi, Adele Tulone, Vito Di Marco, Antonio Craxi, Calogero Camma, Salvatore Petta
Summary: This study aimed to assess the accuracy of AGILE 3+, a score based on various factors, for the diagnosis of advanced fibrosis and the prediction of liver-related events in patients with NAFLD. The results showed that AGILE 3+ had higher diagnostic performance compared to FIB-4 and LSM.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L. Dumitrascu
Summary: After analyzing the role of visfatin in nonalcoholic fatty liver disease, it was found that visfatin levels are not associated with NAFLD, presence or severity of hepatic steatosis, liver fibrosis, lobar inflammation, NASH, and gender.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Eun-Hee Nah, Sug Kyun Shin, Seon Cho, Hyeran Park, Suyoung Kim, Eunjoo Kwon, Han-Ik Cho
Summary: This study investigated the prevalence and distribution of chronic kidney disease (CKD) in individuals with nonalcoholic fatty liver disease (NAFLD) in Korea. The study found that the prevalence of CKD in NAFLD was 12.4%, with albuminuria and proteinuria being more common in NAFLD patients. NAFLD was independently associated with at least mild stage CKD, and there was a significant correlation between CKD and liver fibrosis in NAFLD.
Review
Oncology
James A. Thomas, Bradley J. Kendall, Christine Dalais, Graeme A. Macdonald, Aaron P. Thrift
Summary: Non-alcoholic fatty liver disease (NAFLD) is associated with hepatocellular carcinoma (HCC) and extrahepatic cancer. The incidence rate of HCC is higher in patients with advanced liver fibrosis or cirrhosis, while the incidence rate of extrahepatic cancers is even higher. These findings emphasize the importance of prevention and early detection of cancer in adults with NAFLD.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Medicine, Research & Experimental
Francois Cauchy, Mouniya Mebarki, Benjamin Leporq, Samira Laouirem, Miguel Albuquerque, Simon Lambert, Pierre Bourgoin, Olivier Soubrane, Bernard E. Van Beers, Sandrine Faivre, Pierre Bedossa, Valerie Paradis
Review
Gastroenterology & Hepatology
Pierre Bedossa, Joan Tordjman, Judith Aron-Wisnewsky, Christine Poitou, Jean-Michel Oppert, Adriana Torcivia, Jean-Luc Bouillot, Valerie Paradis, Vlad Ratziu, Karine Clement
Article
Gastroenterology & Hepatology
Gamal Shiha, Alaa Ibrahim, Ahmed Helmy, Shiv Kumar Sarin, Masao Omata, Ashish Kumar, David Bernstien, Hitushi Maruyama, Vivek Saraswat, Yogesh Chawla, Saeed Hamid, Zaigham Abbas, Pierre Bedossa, Puja Sakhuja, Mamun Elmahatab, Seng Gee Lim, Laurentius Lesmana, Jose Sollano, Ji-Dong Jia, Bahaa Abbas, Ashraf Omar, Barjesh Sharma, Diana Payawal, Ahmed Abdallah, Abdelhamid Serwah, Abdelkhalek Hamed, Aly Elsayed, Amany AbdelMaqsod, Tarek Hassanein, Ahmed Ihab, Hamsik GHaziuan, Nizar Zein, Manoj Kumar
HEPATOLOGY INTERNATIONAL
(2017)
Article
Gastroenterology & Hepatology
Hannes Hagstrom, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias, Per Stal, Pierre Bedossa, Rolf Hultcrantz
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2017)
Article
Oncology
Matti Aapro, Alain Astier, Riccardo Audisio, Ian Banks, Pierre Bedossa, Etienne Brain, David Cameron, Paolo Casali, Arturo Chiti, Leticia De Mattos-Arruda, Daniel Kelly, Denis Lacombe, Per J. Nilsson, Martine Piccart, Philip Poortmans, Katrine Riklund, Gunnar Saeter, Martin Schrappe, Riccardo Soffietti, Luzia Travado, Hein van Poppel, Suzanne Wait, Peter Naredi
EUROPEAN JOURNAL OF CANCER
(2017)
Article
Gastroenterology & Hepatology
Julien Bissonnette, Jose Altamirano, Cecile Devue, Olivier Roux, Audrey Payance, Didier Lebrec, Pierre Bedossa, Dominique Valla, Francois Durand, Hafid Ait-Oufella, Pau Sancho-Bru, Joan Caballeria, Pere Gines, Chantal M. Boulanger, Ramon Bataller, Pierre-Emmanuel Rautou
Article
Endocrinology & Metabolism
Pierre Bel Lassen, Frederic Charlotte, Yuejun Liu, Pierre Bedossa, Gilles Le Naour, Joan Tordjman, Christine Poitou, Jean-Luc Bouillot, Laurent Genser, Jean-Daniel Zucker, Nataliya Sokolovska, Judith Aron-Wisnewsky, Karine Clement
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2017)
Article
Gastroenterology & Hepatology
Thomas Karlas, David Petroff, Magali Sasso, Jian-Gao Fan, Yu-Qiang Mi, Victor de Ledinghen, Manoj Kumar, Monica Lupsor-Platon, Kwang-Hyub Han, Ana C. Cardoso, Giovanna Ferraioli, Wah-Kheong Chan, Vincent Wai-Sun Wong, Robert P. Myers, Kazuaki Chayama, Mireen Friedrich-Rust, Michel Beaugrand, Feng Shen, Jean-Baptiste Hiriart, Shiv K. Sarin, Radu Badea, Kyu Sik Jung, Patrick Marcellin, Carlo Filice, Sanjiv Mahadeva, Grace Lai-Hung Wong, Pam Crotty, Keiichi Masaki, Joerg Bojunga, Pierre Bedossa, Volker Keim, Johannes Wiegand
JOURNAL OF HEPATOLOGY
(2017)
Letter
Dermatology
M. Vignon, L. Placais, M. Malphettes, J. D. Bouaziz, B. Asli, P. Bedossa, J. Rivet, R. Szalat, A. M. Zagdanski, M. Rybojad, J. P. Fermand, M. Baron, P. E. Rautou, B. Arnulf
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2017)
Article
Biochemistry & Molecular Biology
Jef Verbeek, Pieter Spincemaille, Ilse Vanhorebeek, Greet Van den Berghe, Ingrid Vander Elst, Petra Windmolders, Jos van Pelt, Schalk van der Merwe, Pierre Bedossa, Frederik Nevens, Bruno Cammue, Karin Thevissen, David Cassiman
LIPIDS IN HEALTH AND DISEASE
(2017)
Article
Gastroenterology & Hepatology
Nicolas Pote, Francois Cauchy, Miguel Albuquerque, Jerome Cros, Olivier Soubrane, Pierre Bedossa, Valerie Paradis
LIVER INTERNATIONAL
(2018)
Article
Gastroenterology & Hepatology
Pierre Bedossa
LIVER INTERNATIONAL
(2017)
Article
Gastroenterology & Hepatology
L. Laurent, C. Lemaitre, A. Minello, A. Plessier, G. Lamblin, A. Poujol-Robert, A. Gervais-Hasenknopf, E. -A. Pariente, P. Belenotti, N. Mostefa-Kara, P. Sogni, M. Legrand, J. -M. Cournac, F. Tamion, G. Savoye, P. Bedossa, D. -C. Valla, V. Vilgrain, O. Goria
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2017)
Article
Gastroenterology & Hepatology
A. Beaufrere, N. Guedj, L. Maggiori, A. Patroni, P. Bedossa, Y. Panis
COLORECTAL DISEASE
(2017)
Article
Gastroenterology & Hepatology
Victor de Ledinghen, Jean-Baptiste Hiriart, Julien Vergniol, Wassil Merrouche, Pierre Bedossa, Valerie Paradis
DIGESTIVE DISEASES AND SCIENCES
(2017)